Jeffrey M. Jonas - 10 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol
SAGE
Transactions as of
10 Feb 2023
Net transactions value
-$514,173
Form type
4
Filing time
10 Feb 2023, 15:42:31 UTC
Previous filing
07 Feb 2023
Next filing
12 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Options Exercise $5,239 +11,643 +9.5% $0.4500* 133,624 10 Feb 2023 Direct
transaction SAGE Common Stock Sale $347,084 -7,805 -5.8% $44.47 125,819 10 Feb 2023 Direct F1, F2
transaction SAGE Common Stock Sale $172,329 -3,838 -3.1% $44.90 121,981 10 Feb 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Options (Right to buy) Options Exercise $0 -11,643 -100% $0.000000* 0 10 Feb 2023 Common Stock 11,643 $0.4500 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This transaction was executed in multiple trades at prices ranging from $43.81 USD to $44.77 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $44.815 USD to $45.03 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017.